28-05-2015 дата публикации
Номер: US20150148334A1
Автор:
Brian S. Freeze,
Masaaki Hirose,
Hong Myung Lee,
Todd B. Sells,
Zhan Shi,
Leo R. Takaoka,
Stepan Vyskocil,
Tianlin Xu,
FREEZE BRIAN S,
HIROSE MASAAKI,
LEE HONG MYUNG,
SELLS TODD B,
SHI ZHAN,
TAKAOKA LEO R,
VYSKOCIL STEPAN,
XU TIANLIN,
FREEZE BRIAN S.,
SELLS TODD B.,
TAKAOKA LEO R.
Принадлежит:
This invention provides compounds of formula I-A or I-B: 517-. (canceled)19. (canceled)2235-. (canceled)3842-. (canceled)43. The compound of claim 37 , wherein Gis N and Gis S.44. (canceled)45. The compound of claim 37 , having the structure VIII-A claim 37 , or a pharmaceutically acceptable salt thereof.48. (canceled)51. The compound of claim 50 , wherein HY is selected from optionally substituted morpholino (iv) or dihydropyran (x).52. The compound of claim 51 , wherein HY is selected from optionally substituted morpholino (iv).53. The compound of claim 37 , wherein Ring A is an optionally substituted phenyl claim 37 , naphthyl claim 37 , quinoline claim 37 , isoquinoline claim 37 , or benzimidazole ring.54. The compound of claim 53 , wherein Ring A is optionally substituted by Rand each occurrence of Ris independently halogen claim 53 , Calkyl claim 53 , —CN claim 53 , Chaloalkyl claim 53 , —OCalkyl claim 53 , OChaloalkyl claim 53 , —NHC(O)Calkyl claim 53 , —NHC(O)NHCalkyl claim 53 , —NHS(O)Calkyl claim 53 , or —C(O)H; and n is 0 to 3.5558-. (canceled)59. The compound of wherein each occurrence of Ris independently hydrogen claim 37 , halo claim 37 , or an optionally substituted group selected from Caliphatic claim 37 , —C(O)N(R) claim 37 , —C(O)OR claim 37 , —CHN(R) claim 37 , —CHOR claim 37 , —CHSR claim 37 , 3-10-membered cycloalphatic claim 37 , 6-10-membered aryl claim 37 , or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen claim 37 , oxygen claim 37 , or sulfur.60. (canceled)61. A composition comprising a compound of and a pharmaceutically acceptable carrier.62. A method of treating a proliferative disorder in a patient comprising administering to said patient a therapeutically effective amount of .63. (canceled)64. A method of treating an inflammatory or cardiovascular disorder in a patient comprising administering to said patient a therapeutically effective amount of .65. (canceled)66. A method for inhibiting PI3K or ...
Подробнее
